Work

FGFR Inhibition in Urothelial Carcinoma

Year: 2024

Type: review

Source: European Urology

DOI: 10.1016/j.eururo.2024.09.012

Authors: Roger Li, Joshua Linscott, James W.F. Catto, Siamak Daneshmand, Bishoy M. Faltas, Ashish M. Kamat, Joshua J. Meeks, Andrea Necchi, Benjamin Pradere, Jeffrey S. Ross, Michiel S. van der Heijden, Bas W.G. van Rhijn, Yohann Loriot

Institutions: Moffitt Cancer Center, University of Sheffield, University of Southern California, Keck Hospital of USC, Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center, Northwestern University, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, SUNY Upstate Medical University, The Netherlands Cancer Institute, Université Paris-Saclay, Institut Gustave Roussy

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Veterans Affairs, National Institute for Health and Care Research, National Institutes of Health, National Cancer Institute

Awards: Genotype of Urothelial cancer: Stratified Treatment and Oncological outcomes (GUSTO): Phase II study, G4506104706, G6078556781, Improving the outcomes from bladder cancer through genomic stratification and novel agents, Somatic Truncation Mutations of the Histone Methyltransferase MLL4 Alter Its Subcellular Localization in Bladder Cancer: Mechanistic Insight and Targeted Therapeutic Approach

OpenAlex ID: W4402974541

FWCI: 4.307

Cites: 58

Cited by: 39

Related to: 10